A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie de Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye
Abstract
: Itolizumab is a promising, safe and effective immunomodulatory therapy for treatment of ARDS due to cytokine release in COVID-19 patients, with survival and recovery-benefit.
Topics & Concepts
MedicineARDSRandomized controlled trialCoronavirus disease 2019 (COVID-19)Acute respiratory distressInternal medicineSurgeryOpen labelLungDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesRespiratory Support and MechanismsLong-Term Effects of COVID-19